Simvastatin attenuates radiation-induced murine lung injury and dysregulated lung gene expression
Novel therapies are desperately needed for radiation-induced lung injury (RILI), which, despite aggressive corticosteroid therapy, remains a potentially fatal and dose-limiting complication of thoracic radiotherapy. We assessed the utility of simvastatin, an anti-inflammatory and lung barrier-protec...
Saved in:
Published in | American journal of respiratory cell and molecular biology Vol. 44; no. 3; pp. 415 - 422 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Thoracic Society
01.03.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Novel therapies are desperately needed for radiation-induced lung injury (RILI), which, despite aggressive corticosteroid therapy, remains a potentially fatal and dose-limiting complication of thoracic radiotherapy. We assessed the utility of simvastatin, an anti-inflammatory and lung barrier-protective agent, in a dose- and time-dependent murine model of RILI (18-(25 Gy). Simvastatin reduced multiple RILI indices, including vascular leak, leukocyte infiltration, and histological evidence of oxidative stress, while reversing RILI-associated dysregulated gene expression, including p53, nuclear factor-erythroid-2-related factor, and sphingolipid metabolic pathway genes. To identify key regulators of simvastatin-mediated RILI protection, we integrated whole-lung gene expression data obtained from radiated and simvastatin-treated mice with protein-protein interaction network analysis (single-network analysis of proteins). Topological analysis of the gene product interaction network identified eight top-prioritized genes (Ccna2a, Cdc2, fcer1 g, Syk, Vav3, Mmp9, Itgam, Cd44) as regulatory nodes within an activated RILI network. These studies identify the involvement of specific genes and gene networks in RILI pathobiology, and confirm that statins represent a novel strategy to limit RILI. |
---|---|
Bibliography: | Originally Published in Press as DOI: 10.1165/rcmb.2010-0122OC on May 27, 2010 This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Author Disclosure: C.T.C. has received a National Institutes of Health (NIH)–sponsored grant (more than $100,000) for research; S.M.D. has received an NIH-sponsored grant (more than $100,000) for research; V.N. has received an NIH-sponsored grant (more than $100,000) for research; Y.A.L. has three patents with Columbia University (Provisional Patent Application: Methods for extracting phenotypic information from the literature via natural language processing, U.S. Patent 20060074991—System and method for generating an amalgamated database. Clinigene. International Patent Application PCT/US03/35470; and Terminological Mapping. Continuation-in-Part of International Patent Application (PCT/US03/35470), and also has a patent with Memorial Sloan Kettering Cancer Center (U.S. Patent 7528116, Kinase suppressor of Ras inactivation for therapy of Ras-mediated tumorigenesis); none of the other authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript. This work was supported by National Institutes of Health grant HL 58,064 (J.G.N.G., V.N., S.M.D.), and by the Ludwig Cancer Foundation (R.R.W.). These authors are co-senior authors of this work. |
ISSN: | 1044-1549 1535-4989 |
DOI: | 10.1165/rcmb.2010-0122OC |